# Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major

> **NCT00658385** · NA · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 5 (actual)

## Conditions studied

- Beta Thalassemia Major
- Congenital Anemias

## Interventions

- **GENETIC:** GCSF, Central venous line placement, Stem cell Collection (leukapheresis)

## Key facts

- **NCT ID:** NCT00658385
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2016-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00658385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00658385, "Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00658385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*